Drug Trial Radar · NCT02589782
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
Last checked: Nov 19, 2026Latest source record: May 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
552
Actual
Start
Jan 2017
Primary completion
Aug 5, 2022
Study completion Aug 5, 2022
Sponsor
- Lead sponsor
- Medecins Sans Frontieres, NetherlandsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- London School of Hygiene and Tropical Medicine; Global Alliance for TB Drug Development; University College, London; Drugs for Neglected Diseases; Swiss Tropical & Public Health Institute; eResearch Technology, Inc.; Ministry of Health, Republic of Uzbekistan; World Health Organization; Ministry of Public Health, Republic of Belarus; THINK TB & HIV Investigative Network; University of Liverpool; Wits Health Consortium (Pty) Ltd; Rutgers, The State University of New Jersey; University of California, San Francisco
- First posted
- Oct 28, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TB PRACTECAL is a multi-centre, open label, multi-arm, randomised, controlled, phase II-III trial; evaluating short treatment regimens containing bedaquiline and pretomanid in combination with existing and re-purposed anti-TB drugs for the treatment of biologically confirmed pulmonary multi drug-resistant TB (MDR-TB).
Conditions
- Tuberculosis, Multidrug-Resistant
- Extensively Drug-Resistant Tuberculosis
- Tuberculosis, Pulmonary
Interventions
BedaquilineDrug
PretomanidDrug
MoxifloxacinDrug
LinezolidDrug
ClofazimineDrug
Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1:Percentage of patients with culture conversion in liquid media at 8 weeks post randomisation.Time frame: 8 weeks post randomisation
- Stage 1: Percentage of patients who discontinue treatment for any reason or dieTime frame: 8 weeks post randomisation
- Stage 2: Percentage of patients with an unfavourable outcome (failure, death, recurrence, loss to follow-up)Time frame: 72 weeks post-randomisation
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital
Minsk, Belarus
Helen Jospeh Hospital
Johannesburg, Gauteng, South Africa
THINK Clinical Trial Unit, Hillcrest
Durban, KwaZulu-Natal, South Africa
King DinuZulu Hospital
Durban, KwaZulu-Natal, South Africa
Doris Goodwin Hospital
Pietermaritzburg, KwaZulu-Natal, South Africa
Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital
Tashkent, Uzbekistan
Republican TB Hospital No. 2
Nukus, Karakalpakstan, Uzbekistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.